WINT.OTC.PinkWindtree Therapeutics INC /DE/
10-Q: Windtree Therapeutics Reports Q1 2025 Results, Highlights Going Concern Uncertainty and New Corporate Strategy
Sentiment:
Quarterly Report
Windtree Therapeutics reports a net loss of $4.0 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also pursuing a new revenue-generating acquisition strategy.
Capital raiseManagement plans to secure additional capital, potentially through a combination of public or private securities offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets.On April 29, 2025, the company entered into a Securities Purchase Agreement for a private placement of Series D Preferred Stock for gross proceeds of approximately $2.5 million.
Worse than expectedThe company reported a net loss of $4.0 million compared to a net income of $10.2 million in the same period last year.The company has expressed substantial doubt about its ability to continue as a going concern.The company's cash and cash equivalents are limited, with sufficient resources only to fund operations through May 2025.
Summary
- Windtree Therapeutics reported a net loss of $4.0 million for the three months ended March 31, 2025, compared to a net income of $10.2 million for the same period in 2024.
- The company's operating loss was $4.09 million, slightly better than the $4.405 million loss in the prior year.
- Research and development expenses were $2.27 million, consistent with $2.253 million in the prior year.
- General and administrative expenses decreased to $1.82 million from $2.152 million.
- As of March 31, 2025, Windtree had cash and cash equivalents of $1.2 million and current liabilities of $6.5 million.
- The company believes it has sufficient resources to fund operations through May 2025.
- There is substantial doubt about Windtree's ability to continue as a going concern for the next 12 months.
- Management plans to secure additional capital through various means, including public or private securities offerings and strategic transactions.
- Windtree is pursuing a new corporate strategy to acquire small companies with FDA-approved products to generate revenue.
- The company's lead product candidate is istaroxime, which is in Phase 2 development for cardiogenic shock.
- Enrollment is ongoing for the SEISMiC C study, with completion anticipated in Q1 2026 and an unblinded data review planned for Q3 2025.
- The company is also developing preclinical SERCA2a activators for heart failure and rostafuroxin for hypertension.
- A 1-for-50 reverse stock split was effected on February 20, 2025.
- On April 29, 2025, the company entered into a Securities Purchase Agreement for a private placement of Series D Preferred Stock for gross proceeds of approximately $2.5 million.
Sentiment
Score: 3
Explanation: The document presents a mixed picture. While the company is pursuing a new strategy and has achieved some positive clinical results, the going concern uncertainty and limited cash resources weigh heavily on the overall sentiment.
Positives
- Operating loss slightly improved compared to the same period last year.
- General and administrative expenses decreased.
- The company is actively pursuing a new strategy to generate revenue through acquisitions.
- Positive topline results were announced from the SEISMiC Extension study in September 2024.
- The company has a licensing agreement with Lees Pharmaceutical (HK) Ltd. for istaroxime in Greater China.
Negatives
- The company reported a net loss of $4.0 million for Q1 2025.
- There is substantial doubt about the company's ability to continue as a going concern.
- Cash and cash equivalents are limited, with sufficient resources only to fund operations through May 2025.
- The company is dependent on securing additional capital to continue its development programs.
- The company has an accumulated deficit of $850.7 million as of March 31, 2025.
Risks
- The company's ability to continue as a going concern is uncertain.
- The company is dependent on securing additional capital, and there is no assurance that it will be able to do so on acceptable terms.
- Failure to raise sufficient capital could force the company to limit or cease its development activities.
- The company's stock price may be subject to delisting from the Nasdaq Capital Market if it fails to comply with listing requirements.
- Clinical trials are subject to risks and uncertainties, and there is no guarantee that istaroxime or other product candidates will be successful.
- The company faces competition from other therapies and products.
- The company is subject to risks associated with international operations, including geopolitical instability and trade tensions.
Future Outlook
The company plans to secure additional capital through various means, including public or private securities offerings and strategic transactions, and is pursuing a new corporate strategy to acquire small companies with FDA-approved products to generate revenue.
Industry Context
The biotechnology industry is characterized by high risk and uncertainty, with many companies facing challenges in securing funding and successfully developing and commercializing their product candidates. Windtree's situation reflects these industry-wide challenges, particularly for smaller companies with limited resources.
Comparison to Industry Standards
- It is difficult to compare Windtree's results directly to industry standards due to its unique pipeline and financial situation.
- However, many small biotech companies face similar challenges in securing funding and advancing their product candidates.
- Companies like Athersys and BioCardia, which are also focused on cardiovascular therapies, have faced similar funding challenges and have had to adjust their development plans accordingly.
- The company's strategy of acquiring revenue-generating assets is similar to that of companies like Ligand Pharmaceuticals, which has built a portfolio of royalty-generating assets through acquisitions and licensing deals.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial situation and going concern uncertainty.
- Employees may be affected by potential cost-cutting measures or changes in the company's operations.
- Customers and partners may be impacted by the company's ability to continue its development programs and commercialize its product candidates.
- Creditors face increased risk of non-payment due to the company's financial difficulties.
Next Steps
- Secure additional capital through various means.
- Continue enrollment in the SEISMiC C study.
- Pursue licensing arrangements and strategic partnerships.
- Advance preclinical SERCA2a activator programs.
- Seek acquisition targets to achieve the company's new corporate strategy.
Key Dates
| Date | Description |
|---|---|
| 2017-10-27 | Date of Exchange and Termination Agreement between Windtree and Deerfield Management Company L.P. |
| 2018-12-31 | CVie Therapeutics acquisition. |
| 2020-03-18 | Date of Term Sheet with Lees Pharmaceutical (HK) Ltd. |
| 2020-09-30 | Date of Aerosurf Funding Term Sheet with Lees Pharmaceutical (HK) Ltd. |
| 2021-01-01 | Start date of Term Sheet with Lee. |
| 2021-12-31 | End date of Term Sheet with Lee. |
| 2022-08-17 | Date of AR License Agreement with Lee. |
| 2022-12-31 | Date of Term Sheet with Lee. |
| 2023-06-30 | Date of Loans Payable With Ipfs Corporation Member. |
| 2023-07-01 | Start date of Loans Payable With Ipfs Corporation Member. |
| 2023-11-09 | Date of LadenburgMemberwint:ATMProgramMember. |
| 2023-12-31 | Date of Loans Payable With Ipfs Corporation Member. |
| 2024-01-12 | Date of License Agreement With Lees Pharmaceutical Hk Ltd Member. |
| 2024-01-17 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-01-18 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-01-19 | Date of License Agreement With Philip Morris Products For Aerosolization Technology Member. |
| 2024-01-24 | Date of Exchange And Termination Agreement With Deerfield Management Company Lp Member. |
| 2024-03-31 | Quarterly period end date. |
| 2024-04-02 | Date of Asset Purchase Agreement With Varian Biopharmaceuticals Inc Member. |
| 2024-04-03 | Date of LadenburgMemberwint:ATMProgramMember. |
| 2024-04-19 | Effective date of 1-for-18 reverse stock split. |
| 2024-04-30 | End date of Loans Payable With Ipfs Corporation Member. |
| 2024-05-09 | Date of Momentum Research Inc Member. |
| 2024-06-25 | Date of June2025SeniorSecuredNotesMember. |
| 2024-06-26 | Date of :MinimumMember. |
| 2024-06-28 | Date of June282024SeniorSecuredNotesMember. |
| 2024-06-30 | Date of ElocPurchaseAgreementMember. |
| 2024-07-01 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-07-02 | Date of License Agreement With Philip Morris Products For Aerosolization Technology Member. |
| 2024-07-03 | Date of July2024SeniorSecuredNotesMember. |
| 2024-07-17 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-07-18 | Date of :July2024FirstPurchaseAgreementMember. |
| 2024-07-19 | Date of -gaap:SubsequentEventMember. |
| 2024-07-22 | Date of wint:CommonStockWarrantLiabilityMember. |
| 2024-07-26 | Date of :July2024SecondPurchaseAgreementMember. |
| 2024-07-29 | Date of wint:CommonStockWarrantLiabilityMember. |
| 2024-07-31 | Date of July2024WarrantsMember. |
| 2024-08-02 | Date of License Agreement With Philip Morris Products For Aerosolization Technology Member. |
| 2024-08-31 | Date of Loans Payable With Ipfs Corporation Member. |
| 2024-09-15 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-09-30 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-10-01 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-10-29 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-10-31 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-11-15 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-11-16 | Date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2024-11-25 | Date of License Agreement With Philip Morris Products For Aerosolization Technology Member. |
| 2024-12-31 | Year end date. |
| 2025-01-01 | Start date of License Agreement With Philip Morris Usa For Aerosolization Technology Member. |
| 2025-01-12 | Date of License, Development and Commercialization Agreement with Lees (HK). |
| 2025-01-24 | Date of Conversion Of SeriesCPreferredStockIntoCommonStockMember. |
| 2025-02-20 | Effective date of 1-for-50 reverse stock split. |
| 2025-03-18 | Date of March2025SeniorSecuredNotesMember. |
| 2025-03-31 | Quarterly period end date. |
| 2025-04-04 | Date of ConvertibleSeniorSecuredNotesMember. |
| 2025-04-29 | Date of -gaap:SubsequentEventMemberwint:April2025SecuritiesPurchaseAgreementMember. |
| 2025-05-02 | Holders of the March 2025 Notes accepted in writing the Companys payoff letter. |
| 2025-05-12 | Date of :April2025SecuritiesPurchaseAgreementMember. |
| 2025-05-15 | Date of report. |
| 2026 | SEISMiC C Study is expected to enroll up to 100 subjects with SCAI Stage C cardiogenic shock with enrollment anticipated to be completed in Q1 2026. |
Keywords
Windtree Therapeutics, istaroxime, cardiogenic shock, heart failure, SEISMiC C study, SEISMiC Extension, SERCA2a activators, rostafuroxin, aPKCi inhibitor, financial results, going concern, capital raise, reverse stock split, FDA-approved products, acquisitions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.